LABU241108C127500
- 9.90
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Natera Analysts Increase Their Forecasts Following Upbeat Results
10 Health Care Stocks With Whale Alerts In Today's Session
Live On CNBC, Joe Terranova Announces Sold Amgen
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
4 Stocks to Watch on Wednesday: AMGN, CSCO and More
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Market-Moving News for November 13th
Baird Maintains Outperform on Natera, Raises Price Target to $160
Natera Analyst Ratings
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Natera Sees FY24 SG&A $775M-$825M; R&D $375M-$400M' Net Cash Inflows $50M-$75M.
Natera Sees FY24 Revenue $1.61B-$1.64B Vs $1.518B Est
Natera Q3 2024 GAAP EPS $(0.26) Beats $(0.58) Estimate, Sales $439.800M Beat $361.450M Estimate
Amgen Analyst Ratings
Amgen Slips as Cantor Cites Safety Concerns Linked to Obesity Candidate
Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial
ARKK's Holdings Ranked by SA Quant Grades
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio